



Non-Insured Health Benefits Program : Update on Infliximab Coverage

Effective **May 1st 2017**, all Non-Insured Benefits Program (NIHB) adult patients who are infliximab-naïve and whose therapy is initiated on or after this date, Inflectra will be the product approved, provided the patient meets the criteria for coverage similar to other biologic therapies. Inflectra is an infliximab biosimilar drug based upon the reference product Remicade. Inflectra was approved by Health Canada and supported by the national Common Drug Review based upon evidence demonstrating no meaningful differences compared to the reference product, but has a significantly lower cost. Inflectra will be reimbursed for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis. Patients who received approval for Remicade before May 1, 2017 will continue to have this brand covered and will also be eligible for coverage of Inflectra.